Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical ProteomicsProgram and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, and biomarker discovery and measurement for direct clinical applications at the bedside. He is a co-founder of 4 life science companies, Theranostics Health, Inc, Ceres Nanosciences Inc., C-4 Diagnostics, Inc. and Perthera, Inc. He is a co-inventor on 40 filed and published patents, and has authored over 350 peer-reviewed publications and invited reviews. He has authored over 40 book chapters, is on the editorial board of Proteomics, Biomedical Microdevices, Proteomics- Clinical Applications, Proteomics- Protocols, Molecular Carcinogenesis, Journal of Personalized Medicine and is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO) as well as the US HUPO and served on the Executive Committee and Treasurer for HUPO from 2002-2004. He is the faculty representative to the George Mason University Research Foundation and represents GMU on the Board of Directors for the Virginia Health Research Biosciences Corporation.